Waters introduces new line of chromatography columns
Waters has launched Acquity Premier Columns, a family of premium sub-2-μm columns that features the company's MaxPeak high-performance surface technology.
Qiagen sales, earnings climb in Q3
Significant ongoing demand for COVID-19 testing and improved trends in other areas of Qiagen's product portfolio led to a 26% increase in preliminary net sales for the company during its third quarter.
Thermo Fisher to add sterile filling lines in Singapore
Thermo Fisher Scientific will operate a $130 million facility in Singapore that will be used to develop two new sterile filling lines, extending capacity to develop and manufacture therapies and vaccines.
FDA grants expanded access for Direct Biologics' ExoFlo
The U.S. Food and Drug Administration (FDA) granted expanded access for Direct Biologics' ExoFlo, allowing it to be used to treat patients with COVID-19-associated acute respiratory distress syndrome.
Atum licenses cell line development tools to Rentschler Biopharma
Rentschler Biopharma has signed a full contract development and manufacturing organization license agreement for Atum's leap-in transposase platform.
ERS Genomics licenses gene editing tech to FASMAC
ERS Genomics, which has access to foundational CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, has signed an agreement with FASMAC of Japan.
Dyno Therapeutics licenses AAV platform to Roche
Dyno Therapeutics has licensed its CapsidMap platform for the development of next-generation adeno-associated virus (AAV) vectors for gene therapies for central nervous system diseases and liver-directed therapies to Roche and its subsidiary Spark Therapeutics.
Boehringer Ingelheim, Oxford BioTherapeutics partner further on antibodies
Boehringer Ingelheim and Oxford BioTherapeutics are partnering to discover novel targets for cancer immunotherapies using the Oxford Genome Anatomy Project's T-cell engager, cancer vaccine, and oncolytic virus platforms.
Moderna gets nod from EMA to submit marketing authorization
Moderna has received written confirmation from the European Medicines Agency (EMA) that messenger RNA (mRNA)-1273, the company's COVID-19 vaccine candidate, is eligible for submission of an application for marketing authorization in the European Union.
J&J pauses COVID-19 vaccine trials
Johnson & Johnson on October 12 temporarily paused further dosing in all of its COVID-19 vaccine clinical trials, including the phase III Ensemble trial, due to an unexplained illness in a study participant.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter